(Protocol EAY191) Molecular Analysis for Combination Therapy Choice (ComboMATCH)

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

For patients aged 18 or older: if your tumor can be biopsied with minimal risk and you have matched to a treatment trial, you will need to have a new biopsy prior to starting treatment. If your tumor can’t be biopsied, you must have tissue available from a previous biopsy that can be used for the study. 

For patients younger than 18 years old, you will be asked if you are willing to: » Submit previously biopsied tissue, if available, or » Have a new optional biopsy for research purposes, if the biopsy can be performed at minimal risk. – The results will be compared to the results that were provided from the ComboMATCH-designated laboratory